News
Thomas Graeber, PhD
Thomas Graeber, PhD, is a Professor in the Department of Molecular & Medical Pharmacology, and the Director of the UCLA Metabolomics Center. Thomas Graeber received his B.S. in Physics from UCLA (1990) and his PhD in Physics/Cancer Biology from Stanford University (1996) with Amato Giaccia studying the role of p53 in hypoxia-induced apoptosis. He is…
Ross Levine, MD
Ross Levine, M.D., is a Member of the Human Oncology and Pathogenesis Program and an Attending Physician on the Leukemia Service, Department of Medicine at Memorial Sloan Kettering (MSK). He is the Laurence Joseph Dineen Chair in Leukemia Research, a Professor of Medicine at Weill Cornell Medical College, and the Director of the MSK Center…
Richard Chesworth, PhD
Dr. Chesworth has more than 20 years of experience in the pharmaceutical and biotechnology industry and has contributed to the research and development programs of thirteen different compounds entering clinical trials, resulting in two clinical approved new molecular entities including tazemetostat recently approved for both epitheloid sarcoma (Jan 2020) and relapsed/refractory follicular lymphoma (June 2020)….
Stéphane de Botton, MD, PhD
Stéphane de Botton, MD is a Physician, Clinical Investigator and head of Drug Development in acute leukemias on the Department of hematology at Gustave Roussy cancer center. He conducts phase I to III clinical trials. He also belongs to the research unit UMR 1170 for novel preclinical research. He is a member of the executive…